Αρχική World News A glucometer for cancer: towards a scalable, universal residual disease measurement World News A glucometer for cancer: towards a scalable, universal residual disease measurement Από Ogkologos - 23 Οκτωβρίου, 2026 51 0 Facebook Twitter Google+ Pinterest WhatsApp Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities 22 Οκτωβρίου, 2021 Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer 26 Οκτωβρίου, 2021 Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer 9 Αυγούστου, 2022 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... 7 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS The right combination for early detection A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... Mom with Breast Cancer Who Had A Year to Live Goes... Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14...
